Commentary|Videos|May 1, 2025
Challenges in Bringing Effective Therapies to Cancer Patients
Author(s)Andy Studna, Senior Editor
In this video interview, C.K. Wang, MD, chief medical officer, COTA, highlights cost and treatment sequencing as some of oncology’s largest hurdles.
Advertisement
In a recent video interview with Applied Clinical Trials, C.K. Wang, MD, chief medical officer, COTA, discussed a recent study he led on leveraging real-world data (RWD) to improve oncology reporting. Additionally, Wang highlighted recent trends and challenges in the oncology research space involving the use of RWD as well as real-world evidence (RWE).
ACT: As an oncologist, what are some of your greatest challenges in bringing the most effective therapies to patients?
Wang: This is an excellent question. There are definitely many challenges that oncologists face day to day when it comes to treating cancer patients, but I would say that two come to mind, as we speak. First and foremost is cost and financial toxicity. Now I will say that this has been a constant through time, but it has definitely become a larger issue with all of our novel therapies. As I think we all know, the majority of these novel therapies are very expensive. This cost is almost always passed on to the patient, and in more cases than not, these costs are just too high for most.
I would say that a second challenge, which has resulted from the rapid explosion of the novel therapies that we see in oncology is the understanding of what is the best sequence to use these new treatments. Our clinical trials are really not the best at helping us with this question as they are conducted only in very specific treatment settings that the sponsor is looking at, and many times they're even compared to therapies that are no longer considered to be the standard of care in that field. Now I will say though that this problem, it is a good problem to have, because in a sense, it shows, and it is the direct result of the vast number of treatments that we have in the field, but to be honest, this is a scenario where too much of a good thing too soon, or in too short of a time period can be a true challenge when it comes to translating all that into real-world everyday clinical practice.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement